The primary objective is to determine the feasibility of delivering OLP-EXP, EXP only, and OLP only over 6 weeks to adults with chronic TMD. The trial will be considered feasible for progression planning when the 6-week retention rate is at least 80% in each arm and average OLP pill adherence is at least 80% of prescribed days in each OLP arm.
Primary hypothesis: Each intervention arm will meet the prespecified 6-week retention benchmark, and each OLP arm will meet the prespecified pill-adherence benchmark.
The secondary objectives are:
Inclusion Criteria:
Exclusion Criteria:
yang.wang@umaryland.edu410-706-7824
In this open-label placebo trial, both the experimenters and participants will be aware of the arms assignment. The outcome assessor will be blinded about the group assignment.
Expectation optimization addressing benefit, personal-control, and coping expectations, plus transparent daily OLP pills for 6 weeks and weekly boosters.
Expectation optimization addressing personal-control and coping expectations associated with chronic pain in general, plus weekly boosters.
Standard transparent OLP rationale and daily OLP pills for 6 weeks, with neutral matched study contacts that do not deliver expectation-optimization content.
Placebo Impacts Sleep and Pain Modulation in Chronic Pain
HOnest Placebos With Explanations: Evaluating Open-Label Placebos for Chronic Pain
Conditioned Open-label Placebos to Facilitate Opioid Reduction in Patients With Subacute or Chronic Pain Pain: a Randomized Controlled Trial
Mindfulness And Placebo for Pain (MAPP) Study
Optimizing Open Label Placebo Rationales
Relieving Acute Pain (RAP) Study: A Pilot Study
OLP-1002 is Being Studied in the Treatment of Pain.
Boosting Open-Label Placebo Effects in Acute Induced Pain in Healthy Adults